DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

BACKGROUND: Treatment options for wild-type BRAF melanoma patients remain limited. Selumetinib, a MEK 1/2 inhibitor, suppresses pERK levels independent of BRAF and NRAS mutation status, and combination with docetaxel has demonstrated synergy in xenograft models. The aim of this study was to assess t...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Gupta, A, Love, S, Schuh, A, Shanyinde, M, Larkin, J, Plummer, R, Nathan, P, Danson, S, Ottensmeier, C, Lorigan, P, Collins, L, Wise, A, Asher, R, Lisle, R, Middleton, MR
Materialtyp: Journal article
Språk:English
Publicerad: Oxford University Press 2014

Liknande verk

Liknande verk